Q32 Bio Inc. shares fall 18.68% intraday as a top premarket decliner.

Q32 Bio Inc. dropped 18.68% in intraday trading, with the company being listed as a top premarket decliner. The company is a clinical-stage biotechnology firm developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis.